Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial - Sorbonne Université Access content directly
Journal Articles Clinical Gastroenterology and Hepatology Year : 2021

Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial

Robert S Rahimi
Rifaat Safadi
  • Function : Author
Kalyan Ram Bhamidimarri
  • Function : Author
Nikolaos Pyrsopoulos
Amy Potthoff
  • Function : Author
Stan Bukofzer
  • Function : Author
Jasmohan S Bajaj

Abstract

Background & aims: Hepatic encephalopathy (HE) is associated with increased morbidity, mortality, and health care resource use. In this phase 2b study, we evaluated the efficacy and safety of ornithine phenylacetate (OP), an ammonia scavenger, in hospitalized patients with cirrhosis, increased levels of ammonia at screening, and acute or overt HE. Methods: We conducted a double-blind study of 231 patients with cirrhosis and HE at multiple sites in North America, Europe, Israel, and Australia from January 7, 2014, through December 29, 2016. Patients were assigned randomly to groups that received placebo or OP (10, 15, or 20 g/d, based on the severity of liver disease), plus each institution's standard of care (eg, lactulose to achieve 2-3 bowel movements with or without rifaximin, in accordance with guidelines). The primary end point was time to confirmed clinical response, defined as reduction to HE staging tool (HEST) stage 2 from baseline HEST stages 3/4 or improvement to HEST stages 0/1 from baseline stage 2, in the intent-to-treat population (all patients with increased levels of ammonia at screening, determined by a local laboratory). Results: Median times to clinical improvement, based on ammonia measurements at local laboratories, did not differ significantly between the groups given OP vs the placebo group (P = .129). Analyses of central laboratory-confirmed increases in levels of ammonia at baseline (n = 201) showed clinical improvement in HE at a median of 21 hours sooner in groups given OP vs placebo. The percentages of patients with any specific adverse event did not differ significantly between groups. Serious adverse events occurred in 25% of patients in the OP group and in 29% in the placebo group (P = .552). Conclusions: In a randomized controlled trial of patients with cirrhosis and HE, we found no significant difference in time to clinical improvement between patients given OP vs placebo. However, OP appears to be safe and should undergo further testing for treatment of hyperammonemia in hospitalized patients receiving treatment for the underlying precipitant of acute or overt HE. ClinicalTrials.gov no: NCT01966419.
Fichier principal
Vignette du fichier
1-s2.0-S1542356520314324-main.pdf (1.29 Mo) Télécharger le fichier
Origin : Publication funded by an institution
Licence : CC BY NC ND - Attribution - NonCommercial - NoDerivatives

Dates and versions

hal-04515224 , version 1 (21-03-2024)

Licence

Attribution - NonCommercial - NoDerivatives

Identifiers

Cite

Robert S Rahimi, Rifaat Safadi, Dominique Thabut, Kalyan Ram Bhamidimarri, Nikolaos Pyrsopoulos, et al.. Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial. Clinical Gastroenterology and Hepatology, 2021, 19 (12), pp.2626-2635.e7. ⟨10.1016/j.cgh.2020.10.019⟩. ⟨hal-04515224⟩
0 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More